Development, Commercialization and Supply Agreements (Tables)

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Product Approval

The Company received approval of VASCEPA under the MARINE and REDUCE-IT indications in the following countries:

Country	MARINE	REDUCE-IT		Launch Date
Lebanon	March 2018	August 2021		June 2018
United Arab Emirates	July 2018	October 2021		February 2019
Qatar	December 2019	April 2021			—
Bahrain	April 2021	April 2022			—
Kuwait	December 2021	March 2023			—
Saudi Arabia	March 2022		—		—

Changes in Balances of Contract Assets and Liabilities and Revenues Recognized

The following table presents changes in the balances of the Company’s contract assets and liabilities during the three months ended March 31, 2023 and 2022:

In thousands	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Three months ended March 31, 2023:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	15,346	$	—	$	(445	)	$	14,901
Three months ended March 31, 2022:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	16,709	$	—	$	(372	)	$	16,337

During the three months ended March 31, 2023 and 2022, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods:

In thousands	Three months ended March 31,
Revenue recognized in the period from:	2023		2022
Amounts included in contract liability at the beginning of the period	$	445	$	372